カタログ製品コード : C-EK1212-96
Human Prostate-Specific Antigen/PSA ELISA kit
24T | ¥47,000 | (¥1,958/T) (税別) |
48T | ¥61,000 | (¥1,271/T) (税別) |
96T | ¥69,800 | (¥727/T) (税別) |
標準納期 : 2週間 |
カタログ製品コード : C-EK1212-96
Human Prostate-Specific Antigen/PSA ELISA kit
24T | ¥47,000 | (¥1,958/T) (税別) |
48T | ¥61,000 | (¥1,271/T) (税別) |
96T | ¥69,800 | (¥727/T) (税別) |
標準納期 : 2週間 |
メーカー名 | 遺伝子名 | 種交差性 | 測定範囲 | サンプル量 | 適用サンプル | ドキュメント |
---|---|---|---|---|---|---|
MultiSciences | Prostate-Specific Antigen/PSA | Human Prostate-Specific | 0.63 - 40 ng/ml | 50 μl | 血清、血漿、細胞培養上清 |
■保存方法 :
キットは未開封の場合、4℃で保管すること。 開封後は標準溶液を-20℃で保存し、他の試薬は4℃で保存すること。
■構成内容 :
96-well polystyrene microplate coated with a monoclonal antibody against PSA |
Human PSA Standard, lyophilized |
PSA Detect Antibody |
Standard Diluent |
Assay Buffer (10×) |
Substrate (TMB) |
Stop Solution |
Washing Buffer (20×) |
Plate Covers |
■キーワード :
Homo sapiens,Human,Prostate-specific antigen,PSA,Gamma-seminoprotein,Seminin,Kallikrein-3,P-30 antigen,Semenogelase,KLK3,APS,3.4.21.77
■ターゲット情報 :
This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human PSA. The Human Prostate-Specific Antigen/PSA ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland. PSA is produced for the ejaculate, where it liquefies semen in the seminal coagulum and allows sperm to swim freely. It is also believed to be instrumental in dissolving cervical mucus, allowing the entry of sperm into the uterus.
PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. Obesity has been reported to reduce serum PSA levels. PSA levels can be also increased by prostatitis, irritation and benign prostatic hyperplasia producing a false positive result. PSA is not a unique indicator of prostate cancer, but may also detect prostatitis or benign prostatic hyperplasia. 30 percent of patients with high PSA have prostate cancer diagnosed after biopsy. Clinical practice guidelines for prostate cancer screening vary and are controversial due to uncertainty as to whether the benefits of screening ultimately outweigh the risks of overdiagnosis and over treatment.